

浏览全部资源
扫码关注微信
1.北京中医药大学 中药学院,北京 100029
2.北京同仁堂股份有限公司 科学研究所, 北京 100079
3.北京中医药大学 东方医院,北京 100078
Received:11 July 2024,
Published Online:13 September 2024,
Published:20 December 2024
移动端阅览
田时秋,左泽平,田颖颖等.基于胆固醇代谢途径相关蛋白探讨丹荷颗粒对高胆固醇血症大鼠的作用[J].中国实验方剂学杂志,2024,30(24):85-94.
TIAN Shiqiu,ZUO Zeping,TIAN Yingying,et al.Effect of Danhe Granules on Hypercholesterolemia Rats Based on Cholesterol Metabolism Pathway-related Proteins[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(24):85-94.
田时秋,左泽平,田颖颖等.基于胆固醇代谢途径相关蛋白探讨丹荷颗粒对高胆固醇血症大鼠的作用[J].中国实验方剂学杂志,2024,30(24):85-94. DOI: 10.13422/j.cnki.syfjx.20241404.
TIAN Shiqiu,ZUO Zeping,TIAN Yingying,et al.Effect of Danhe Granules on Hypercholesterolemia Rats Based on Cholesterol Metabolism Pathway-related Proteins[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(24):85-94. DOI: 10.13422/j.cnki.syfjx.20241404.
目的
2
观察丹荷颗粒干预下高胆固醇血症大鼠的药效指标及胆固醇代谢途径相关蛋白水平的变化,研究丹荷颗粒对高胆固醇血症大鼠的治疗作用及机制。
方法
2
将SD大鼠按体质量随机分为空白组和模型组,空白组以维持饲料喂养,模型组持续给予高脂饲料喂养7周。造模1周后检测模型大鼠血清总胆固醇(TC)含量,按TC值将模型组随机分为模型组、普伐他汀钠片组(4.02 mg·kg
-1
)、血脂康胶囊组(0.12 g·kg
-1
)、丹荷颗粒高、中、低剂量组(4.536、2.268、1.134 g·kg
-1
);模型组分组后,各给药组连续灌胃给药6周,期间每周称体质量1次,每周称取1次饲料加入量与饲料剩余量的差值为摄食量,6周后检测血清TC、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平,采用苏木素-伊红(HE)染色与油红O染色,观察肝脏病理状态和脂滴分布情况,进行评分和计算。采集大鼠肝脏,运用蛋白免疫印迹法(Western blot)和免疫组化法(IHC)检测高胆固醇血症大鼠胆固醇代谢相关蛋白磷酸化的腺苷酸活化蛋白激酶(p-AMPK)、腺苷酸活化蛋白激酶(AMPK)、3-羟基-3-甲基戊二酸单酰辅酶A还原酶(HMGCR)、低密度脂蛋白受体(LDLR)、胆固醇7
α
-羟化酶(CYP7A1)、乙酰辅酶A乙酰转移酶2(ACAT2)、载脂蛋白B(ApoB)的表达水平。
结果
2
与空白组比较,模型组血清TC水平显著升高(
P<
0.01),TG水平变化差异无统计学意义,HDL-C水平明显降低(
P<
0.05),肝脏指数、脂肪变性评分、病理状态总得分及油红O染色的阳性面积比率显著升高(
P<
0.01),p-AMPK、p-AMPK/AMPK、LDLR、CYP7A1蛋白表达水平明显降低(
P<
0.05,
P<
0.01),AMPK、HMGCR、ACAT2蛋白表达水平明显升高(
P<
0.05,
P<
0.01)。与模型组比较,丹荷颗粒各剂量组TC水平明显降低(
P<
0.05),普伐他汀钠片组和丹荷颗粒中剂量组油红O染色的阳性面积比率明显降低(
P<
0.05);各给药组p-AMPK、p-AMPK/AMPK蛋白表达水平明显升高(
P<
0.05,
P<
0.01),HMGCR、ACAT2水平显著降低(
P<
0.01),ApoB水平有下降的趋势;普伐他汀钠片组和丹荷颗粒各剂量组CYP7A1水平明显升高(
P<
0.05,
P<
0.01),普伐他汀钠片组、血脂康胶囊组和丹荷颗粒高、中剂量组LDLR水平明显升高(
P<
0.05,
P<
0.01)。
结论
2
丹荷颗粒可降低血清TC水平,改善肝脏脂肪变性。可能通过激活AMPK,下调HMGCR的表达,抑制胆固醇的合成;上调LDLR和CYP7A1表达,促进胆固醇的摄取与排泄;下调ACAT2和ApoB的表达,减少胆固醇的吸收和LDL等脂蛋白的装配;发挥治疗高胆固醇血症的作用。
Objective
2
To explore the therapeutic effect and mechanism of the Danhe granules on hypercholesterolemia rats by observing the changes in the efficacy indicators and the levels of proteins related to the cholesterol metabolism pathway in the rats under the intervention of Danhe granules.
Method
2
SD rats were randomly assigned to either the blank group or the model group based on their body weight. The blank group had normal chow diets, while the model group was fed high-fat diets for seven weeks. One week after the establishment of the model, the content of the serum total cholesterol (TC) in the model rats was detected. According to the TC value, the model group was further randomly divided into a control group, pravastatin sodium tablet group(4.02 mg·kg
-1
), Xuezhikang capsule group(0.12 g·kg
-1
), high-dose, middle-dose, and low-dose groups of Danhe granules(4.536, 2.268, 1.134 g·kg
-1
). After grouping the model groups, each
treatment group received continuous oral gavage for six weeks, with weekly measurements of body weight and food intake (the difference between feed intake and feed surplus). Six weeks later, the levels of serum TC, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. The liver pathology and lipid droplet distribution were evaluated by hematoxylin-eosin (HE) staining and oil red O staining, with scoring and calculation conducted. Rat liver tissue was collected, and western blot and immunohistochemistry (IHC) were used to detect the expression levels of cholesterol metabolism-related proteins namely phosphorylated adenosine 5'-monophosphate (AMP)-activated protein kinase (p-AMPK), AMPK, 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR), low-density lipoprotein receptor (LDLR), cholesterol 7
α
-hydroxylase (CYP7A1), Acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2), and apolipoprotein B (ApoB) in hypercholesterolemia rats.
Result
2
Compared with the blank group, the model group showed a significantly higher level of serum TC (
P
<
0.01). The TG level had no significant change, and the HDL-C level was significantly decreased (
P
<
0.05). The liver index, steatosis score, total score of pathological state, and the positive area ratio of oil red O staining were significantly increased (
P
<
0.01), and the protein expression levels of p-AMPK, p-AMPK/AMPK, LDLR, and CYP7A1 were significantly decreased (
P
<
0.05,
P
<
0.01), while the protein expression levels of AMPK, HMGCR, and ACAT2 were significantly increased (
P
<
0.05,
P
<
0.01). Compared with the model group, the TC level in each dose group of Danhe granules was significantly decreased (
P
<
0.05), and the positive area ratio of oil red O staining in the pravastatin sodium tablet group and medium-do
se group of Danhe granules was significantly decreased (
P
<
0.05). In each administration group, the protein expression levels of p-AMPK and p-AMPK/AMPK were significantly increased (
P
<
0.05,
P
<
0.01), and the levels of HMGCR and ACAT2 were significantly decreased (
P
<
0.01). The ApoB level showed a downward trend. The CYP7A1 level in the pravastatin sodium tablet group and each dose group of Danhe granules was significantly increased (
P
<
0.05,
P
<
0.01), and the LDLR level in the pravastatin sodium tablet group, Xuezhikang capsule group, and high-dose and medium-dose groups of Danhe granules was significantly increased (
P
<
0.05,
P
<
0.01).
Conclusion
2
Danhe granules can reduce serum TC levels and improve hepatic steatosis. It may activate AMPK, down-regulate the expression of HMGCR, and inhibit cholesterol synthesis. It can also up-regulate the expression of LDLR and CYP7A1, promote cholesterol uptake and excretion, down-regulate the expression of ACAT2 and ApoB, reduce cholesterol absorption and assembly of LDL and other lipoproteins, and thus play a role in the treatment of hypercholesterolemia.
YANG L , LI Z , SONG Y , et al . Study on urine metabolic profiling and pathogenesis of hyperlipidemia [J]. Clin Chim Acta , 2019 , 495 : 365 - 373 .
LIU T , ZHAO D , QI Y . Global trends in the epidemiology and management of dyslipidemia [J]. J Clin Med , 2022 , 11 ( 21 ): 6377 .
吴晶魁 , 杨乔 . 中药水蛭对高脂血症大鼠脂质代谢及肝脏的影响 [J]. 中国中药杂志 , 2018 , 43 ( 4 ): 794 - 799 .
张荣展 , 汤甜甜 , 黄芳 , 等 . 基于内质网自噬系统探究泽泻汤对高脂血症急性胰腺炎的防治作用 [J]. 中草药 , 2024 , 55 ( 11 ): 3705 - 3715 .
HIRANO T . Pathophysiology of diabetic dyslipidemia [J]. J Atheroscler Thromb , 2018 , 25 ( 9 ): 771 - 782 .
王增武 , 刘静 , 李建军 , 等 . 中国血脂管理指南(2023年) [J]. 中国循环杂志 , 2023 , 38 ( 3 ): 237 - 271 .
REAMY B V , FORD B , GOODMAN C . Novel pharmacotherapies for hyperlipidemia [J]. Prim Care , 2024 , 51 ( 1 ): 27 - 40 .
张宝珍 , 张凯 . 从发展战略角度观中医药防治血脂紊乱的优势与挑战 [J]. 解放军医药杂志 , 2019 , 31 ( 5 ): 109 - 112 .
潘绮雪 , 陈奎奎 , 马兆臣 , 等 . 基于体内暴露量的丹荷颗粒质量标志物研究 [J]. 中草药 , 2021 , 52 ( 9 ): 2608 - 2616 .
孟祥茹 , 张振 , 王红伟 , 等 . 丹参多酚酸盐对动脉粥样硬化大鼠血流动力学和血液流变学的影响 [J]. 中国循证心血管医学杂志 , 2017 , 9 ( 8 ): 920 - 923 .
CHOI E K , CHO Y J , YANG H J , et al . Coix seed extract attenuates the high-fat induced mouse obesity via PPAR γ and C/EBP α a downregulation [J]. Mol Cell Toxicol , 2015 , 11 ( 2 ): 213 - 221 .
张志清 , 潘秋 , 于彤 , 等 . 中药虎杖单体及其复方调脂作用的系统评价 [J]. 世界中医药 , 2022 , 17 ( 19 ): 2747 - 2752,2758 .
林思 , 秦慧真 , 邓玲玉 , 等 . 虎杖苷药理作用及机制研究进展 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 22 ): 241 - 250 .
YE X L , HUANG W W , CHEN Z , et al . Synergetic effect and structure-activity relationship of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors from Crataegus pinnatifida Bge [J]. J Agric Food Chem , 2010 , 58 ( 5 ): 3132 - 3138 .
陈奇 , 张柏礼 . 中药药效研究方法学 [M]. 北京 : 人民卫生出版社 , 2016 : 459 .
陈少影 , 李晶晶 , 兰卫 . 常用中药有效成分降脂作用研究进展 [J]. 中国实验方剂学杂志 , 2023 , 29 ( 13 ): 241 - 253 .
国家食品药品监督管理局 . 国食药监保化 [2012] 107号关于印发抗氧化功能评价方法等9个保健功能评价方法的通知 附件6 .辅助降血脂评价方法[Z]. 2012-04-23 .
CORTES V A , BUSSO D , MAIZ A , et al . Physiological and pathological implications of cholesterol [J]. Front Biosci (Landmark Ed) , 2014 , 19 ( 3 ): 416 - 428 .
LUO J , YANG H , SONG B L . Mechanisms and regulation of cholesterol homeostasis [J]. Nat Rev Mol Cell Biol , 2020 , 21 ( 4 ): 225 - 245 .
ONG F S , DEIGNAN J L , KUO J Z , et al . Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics:A challenge for clinical implementation [J]. Pharmacogenomics , 2012 , 13 ( 4 ): 465 - 475 .
WAIZ M , ALVI S S , KHAN M S . Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management [J]. EXCLI J , 2022 , 21 : 47 - 76 .
NIE Y , LUO F . Dietary fiber:An opportunity for a global control of hyperlipidemia [J]. Oxid Med Cell Longev , 2021 , 2021 : 5542342 .
PULLINGER C R , ENG C , SALEN G , et al . Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype [J]. J Clin Invest , 2002 , 110 ( 1 ): 109 - 117 .
YANG H X , ZHANG M , LONG S Y , et al . Cholesterol in LDL receptor recycling and degradation [J]. Clin Chim Acta , 2020 , 500 : 81 - 86 .
宗毓麟 , 孙月蒙 , 孙燕 , 等 . 当归芍药散及其拆方对动脉粥样硬化小鼠血脂及炎症介质的影响 [J]. 世界中医药 , 2023 , 18 ( 9 ): 1230 - 1235 .
OHSHIRO T , MATSUDA D , SAKAI K , et al . Pyripyropene A, an acyl-coenzyme A:Cholesterol acyltransferase 2-selective inhibitor,attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia [J]. Arterioscler Thromb Vasc Biol , 2011 , 31 ( 5 ): 1108 - 1115 .
LEE R G , KELLEY K L , SAWYER J K , et al . Plasma cholesteryl esters provided by lecithin:Cholesterol acyltransferase and acyl-coenzyme A:Cholesterol acyltransferase 2 have opposite atherosclerotic potential [J]. Circ Res , 2004 , 95 ( 10 ): 998 - 1004 .
WILCOX L J , BORRADAILE N M , DE DREU L E , et al . Secretion of hepatocyte ApoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP [J]. J Lipid Res , 2001 , 42 ( 5 ): 725 - 734 .
HEVONOJA T , PENTIKäINEN M O , HYVÖNEN M T , et al . Structure of low density lipoprotein (LDL) particles:Basis for understanding molecular changes in modified LDL [J]. Biochim Biophys Acta , 2000 , 1488 ( 3 ): 189 - 210 .
丁银润 . 主要食药用菌降血脂作用及其机理研究 [D]. 广州 : 华南理工大学 , 2017 .
SNIDERMAN A D , THANASSOULIS G , GLAVINOVIC T , et al . Apolipoprotein B particles and cardiovascular disease:A narrative review [J]. JAMA Cardiol , 2019 , 4 ( 12 ): 1287 - 1295 .
CARR S S , HOOPER A J , SULLIVAN D R , et al . Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment [J]. Pathology , 2019 , 51 ( 2 ): 148 - 154 .
0
Views
129
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621